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1. Introduction 
Radiation treatment is an important therapeutic option for a number of malignancies 
(American Cancer Society), but its use is frequently limited by adverse effects on normal 
tissues (Stone et al., 2003). Thus, the goal of most oncology treatments is to maximize the 
antineoplastic effect while minimizing deleterious outcomes for the patient. WR-2721 was 
developed by the U.S. Army Anti-Radiation Drug Development Program for its potential to 
protect against damage caused by ionizing radiation (Yuhas &Stoner, 1969). Today, WR-
2721 is known as amifostine (Ethyol®; MedImmune Oncology, Inc., Gaithersburg, MD). 
Initial preclinical studies demonstrated that amifostine could protect treated mice from 
lethal doses of radiation, and this protection did not extend to transplanted mammary 
tumor cells (Yuhas &Stoner, 1969).  
Amifostine, a thiol that protects cells from damage by scavenging oxygen-derived free 
radicals, was later evaluated for a potential role in reducing the toxicities from radiation and 
chemotherapeutic agents, such as alkylating agents and platinum agents. In contrast to organ-
specific protectants, amifostine is considered a broad-spectrum cytoprotective agent (Hensley 
et al., 1999). Preclinical studies demonstrated that amifostine can selectively protect almost all 
normal tissues from the cytotoxic effects of some chemotherapeutic agents and radiation 
therapy. Neoplastic tissues do not benefit from amifostine's protection (Koukourakis, 2003; 
Sasse et al., 2006; Yuhas et al., 1980). Amifostine is an inactive prodrug that cannot protect until 
dephosphorylated to the active metabolite, WR-1065, by alkaline phosphatase in the plasma 
membrane (Calabro-Jones et al., 1985). The selective protection of normal tissue is the result of 
a greater accumulation of WR-1065 in normal tissues than in tumor cells. Tumors are relatively 
hypovascular, thus resulting in comparative hypoxia and a low interstitial pH. Furthermore, 
alkaline phosphatase expression is reduced in malignant tissues. Taken together, the 
combination of hypovascularity, low pH, and reduced enzyme levels results in low 
accumulation of active drug in tumor tissues. Thus, normal tissues may be able to maintain as 
much as a 100-fold greater concentration of the free thiol than tumor tissue (Yuhas, 1980).  
Once inside the cell, WR-1065 scavenges free radicals, protecting cellular membranes and 
DNA from damage. However, other studies have suggested that additional mechanisms 
may also play important roles in the action of amifostine. In vitro studies have shown that 
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oxidation of WR-1065 to its polyamine-like disulfide metabolite (WR-33278) is followed by a 
rapid consumption of oxygen in culture medium, suggesting that induction of cellular 
anoxia may be a mechanism for radioprotection (Purdie et al., 1983). This was supported by 
a study by Glover et al. that showed a rapid increase in the oxygen saturation of the venous 
blood after i.v. administration of amifostine without affecting the oxygen dissociation curves 
of hemoglobin, again suggesting that a decrease in oxygen consumption by normal tissues 
may be involved in amifostine-related radioprotection (Glover et al., 1984). In another study, 
high concentrations of WR-33278 condensed DNA, thereby limiting potential target sites for 
free-radical attack (Savoye et al., 1997). This activity would clearly account for a decrease in 
the number of double-strand breaks after radiotherapy, in turn leading to a reduction of the 
transient block at the G2 phase of cell division induced by radiation (Rubin et al., 1996). The 
enhanced cellular proliferation that results from a reduction in damage to DNA may be an 
important pathway to accelerated recovery of endothelial tissues that are affected soon after 
radiation exposure (Rubin et al., 1996) and seems to be important for the recovery of 
irradiated mucosa (Koukourakis et al., 1999). In addition, amifostine, indirectly through 
hypoxia, may upregulate the expression of a variety of proteins involved with DNA repair 
and inhibition of apoptosis, such as Bcl-2 and hypoxia-inducible factor-1 (Carmeliet et al., 
1998; Kajstura et al., 1996; Shimizu et al., 1996).  
Early phase I trials with amifostine were not able to demonstrate a maximum-tolerated dose 
but did establish a tolerable dose range of 740–910 mg/m2 for use in phase II studies 
(Blumberg et al., 1982). Amifostine is generally well tolerated, although transient adverse 
events may be dose related and include hypotension, nausea, vomiting, sneezing, 
somnolence, a metallic taste during infusion, and occasional allergic reactions that may 
include rash, fever, and anaphylactic shock (Blumberg et al., 1982). Although hypotension is 
the most clinically significant adverse event, treatment interruptions caused by a significant 
decline in blood pressure are rare, occurring in <5% of patients receiving amifostine. Emesis 
can be reduced with judicious use of an antiemetic regimen before amifostine 
administration. Transient hypocalcemia caused by inhibition of parathyroid hormone 
secretion has also been reported (Glover et al., 1983). The incidence and severity of 
amifostine-related adverse events have been shown to vary based on the route of 
administration. A recent meta-analysis of randomized studies using amifostine reported a 
significantly greater risk for grade 3 or 4 hypotension when amifostine was administered as 
a slow i.v. infusion (Sasse et al., 2006). Studies examining the s.c. administration of 
amifostine have demonstrated a lower incidence of hypotension and nausea/vomiting than 
with i.v. administration (Koukourakis et al., 2000; Anne & Curran, 2002; Anne et al., 2007). 
However, s.c. administration of amifostine has been reported to be associated with a higher 
incidence of fever and cutaneous reactions than with i.v. administration in these studies 
(Sasse et al., 2006; Koukourakis et al., 2000; Anne & Curran, 2002; Anne et al., 2007).  
Pharmacokinetic studies in patients have demonstrated that amifostine is rapidly cleared 
from the plasma compartment, with a half-life of <1 minute, and >90% cleared within 6 
minutes (Shaw et al., 1986). However, very little amifostine, or the metabolites WR-1065 and 
WR-33278, is excreted in urine 1 hour after injection. These data show that once amifostine 
enters the plasma, it is rapidly metabolized and distributed in the tissues, whereas the 
excretion of the metabolic products is very slow. Timely administration of amifostine 
relative to radiation or chemotherapeutic treatment is necessary. One study by Buentzel et 
al., in which amifostine was administered 30 minutes before chemoradiotherapy, 
demonstrated no significant difference in the incidence of grade 2 acute or chronic 
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xerostomia or grade 3 oral mucositis between patients receiving i.v. amifostine and those 
receiving placebo (Buentzel et al., 2006). On days when combined radiochemotherapy was 
administered, timing between amifostine and radiotherapy may have exceeded 60 minutes. 
The authors suggest that timing of the amifostine doses relative to the beginning of 
radiotherapy may have influenced efficacy because of inadequate exposure to amifostine. In 
addition, the observed rates of grade 2 acute xerostomia and grade 3 oral mucositis in the 
placebo group were unexpectedly low, reducing the ability of the study to show significant 
benefit with amifostine. In contrast, studies in which amifostine was administered within 30 
minutes of radiotherapy have shown promise with regard to protection from acute and 
chronic xerostomia (Andonadou et al., 2002; Brizel et al., 2000; Vacha et al., 2003). Taken 
together, it appears that administration of amifostine within 30 minutes of radiotherapy or 
chemoradiotherapy may provide optimal benefit for cytoprotection of normal tissues.  
Of primary concern with the use of any substance or technique that is intended to spare 
normal tissues from treatment-related toxicities is the unintended and undesirable 
protection of tumor cells. Clearly, procedures that protect tumors are not clinically useful. A 
recent meta-analysis of the available clinical data concluded that, in addition to reducing the 
toxicities associated with radiation therapy, amifostine does not affect the efficacy of 
radiotherapy (Sasse et al., 2006). To the contrary, patients receiving amifostine with 
radiotherapy achieved higher rates of complete response, presumably the result of fewer 
treatment interruptions because of reduced acute toxicity of the treatment.  
1.1 Xerostomia and oral mucositis 
Xerostomia and mucositis are significant and potentially debilitating toxicities associated 
with radiation therapy. The risk for these complications depends on the area receiving 
radiation, the dose and schedule of therapy, whether radiation therapy is combined with 
chemotherapy, and other factors (Sonis & Fey, 2002). Although rarely life threatening, the 
acute and long-term consequences can be significant, causing discomfort, reduced nutrition, 
and a diminished quality of life. Xerostomia is the most common toxicity associated with 
standard fractionated radiation therapy to the head and neck. Whereas acute xerostomia 
from radiation is the result of an inflammatory reaction, late xerostomia, observed 1 year 
after radiation, is usually a permanent result of fibrosis of the salivary gland. The dry mouth 
of xerostomia affects the patient's ability to eat and speak. The decreased salivary output in 
patients with xerostomia can be responsible for an increased risk for dental caries, oral 
infections, and osteonecrosis.  
The results of numerous randomized controlled studies suggest that amifostine may protect 
against radiation- and chemoradiation-induced toxicity in patients with head and neck 
cancer (Table 1) (Sasse et al., 2006). In one study by Buntzel et al., 28 patients received 
radiation therapy in conjunction with carboplatin (Buntzel et al., 1998). Amifostine was 
administered to 14 patients on the day of carboplatin at a fixed dose of 500 mg (equivalent to 
250–340 mg/m2). Acute grade 3 or 4 mucositis was experienced by 12 of 14 patients (86%) 
treated with radiochemotherapy alone compared with none of the amifostine-treated  
patients (p < .001). Additionally, at a 12-month follow-up, 17% of patients who received 
amifostine experienced late grade 2 xerostomia, compared with 55% of the patients treated 
without amifostine (p = .05). An international phase III trial of radiation therapy with and 
without amifostine was conducted in 315 patients with squamous cell carcinoma of the head  
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Study Number 
of patients
Treatment Main conclusions 
RT    
McDonald et at., 1994  9 RT + i.v, amifostine, 
100 mg/m2 
Flow rates of unstimulated whole 
saliva recovered to 20% of baseline at 
12 months post-treatment 
Wagner etal., 1998 14 RT 4· i.v. 
amifostine. 200 
mg/m2 
i.v. amifostine treatment led to 
significant reduction in oral 
symptoms and duration of mucositis 
Bourhis et al., 2000 26 RT + i.v. amifostine, 
150 mg/m2, versus 
RT alone 
i.v. amifostine treatment led to 
significant reduction in duration of 
acute mucositis and duration of 
feeding tube use compared with RT 
treatment alone 
Koukourakis et al., 2000 40 RT + s.c. amifostine, 
500 mg, versus RT 
alone 
s.c. amifostine led to significant 
reduction in severity of oral mucositis 
compared with RT treatment alone 
Brizel et al., 2000 315 RT + i.v. amifostine, 
200 mg/m2, versus 
RT alone 
i.v. amifostine led to significant 
reduction in acute and chronic 
xerostomia versus RT alone and 
increased saliva production versus RT 
alone; no significant reduction in 
grade ≥3  mucositis versus RT 
Wasserman et al., 2005 315 2-yr follow-up of 
Brizel etal. (2000) 
[26] 
i.v. amifostine led to significant 
decrease in severity and duration of 
xerostomia at 2 yrs post-treatment 
without compromising tumor control 
Anne el al., 2002, 2007  54 RT + s.c. amifostine, 
500 mg 
Incidence of acute grade ≥2 
xerostomia, 56%; 1-yr rates of 
locoregional tumor control, 
progression-free survival, and overall 
survival, 78%, 75%, and 85%, 
respectively 
RCT    
Buntzel et al., 1998 
 
39 RT + carboplatin + 
i.v. amifostine. 500 
mg, versus RT + 
carboplatin 
(control) 
i.v. amifostine treatment led to 
significant reductions in acute 
xerostomia, grade ≥3 mucositis, and 
grade ≥3 thrombocytopenia compared 
with control treatment 
Peters et al., 1999 28 RT + carboplatin + 
i.v. amifostine, 500 
mg, versus RT + 
carboplatin 
(control) 
i.v. amifostine treatment had no 
significant effect on xerostomia or 
mucositis compared with control 
treatment 
Atttonadou et al., 2002 50 RT + carboplatin + 
i.v. amifostine, 300 
mg/m2, versus RT 
+ carboplatin 
(control) 
i.v. amifostine treatment led to 
significant reduction in acute and late 
grade ≥2 xerostomia and grade ≥3 
mucositis compared with control 
treatment 
www.intechopen.com
 
The Cytoprotective Effect of Amifostine Against Radiation Induced Toxicity 
 
261 
Study Number 
of patients
Treatment Main conclusions 
Vacha et al., 2003 52 RT + carboplatin + 
i.v. amifostine. 250 
mg, versus RT + 
carboplatin 
(control) 
i.v. amifostine treatment led to 
significant reduction in xerostomia 
compared with control treatment: 
reduction in mucositis was not 
significant between treatment groups 
Bucntzel et al., 2006 132 RT + carboplatin + 
i.v, amifostine, 200-
300 mg/ m2, versus 
RT + carboplatin 
(control) 
No difference between i.v, amifostine 
treatment and control treatment with 
regard to incidence of grade ≥2 
xerostomia or grade ≥3 mucositis: low 
incidence of grade ≥2 xerostomia and 
grade ≥3 mucositis in control patients; 
no evidence of tumor protection was 
Observed with either treatment 
Abbreviations: CRT, radiochemotherapy: RT, radiotherapy. 
Table 1. Clinical trials of amifostine therapy during radiation therapy or radiochemotherapy 
for head and neck cancer 
and neck in which at least 75% of each parotid gland was present in the radiation fields 
(Brizel et al., 2000). The amifostine dose was 200 mg/m2 daily, 15–30 minutes before each 
fraction of radiation therapy (1.8–2.0 Gy/day, 5 days per week for 5–7 weeks, to a total 
dose of 50–70 Gy). Amifostine significantly reduced acute and late xerostomia and 
associated symptoms. Using Radiation Therapy Oncology Group (RTOG) grading criteria, 
patients receiving amifostine had a lower incidence of grade 2 or higher acute xerostomia 
(51% versus 78%; p < .001) and a lower incidence of grade 2 or higher late xerostomia 
(34% versus 57%; p = .002). The proportion of patients with meaningful saliva production 
after 1 year was significantly higher with amifostine (72% versus 49%; p = .003). Despite a 
trend toward lower severity of mucositis with amifostine (p = .14), the difference in the 
incidence of grade 3 or higher mucositis was not statistically significant (p = .48). 
Importantly, at 1 year, with a median follow-up of 20 months, the locoregional tumor 
control rates did not differ, and disease-free and overall survival times were comparable. 
Two-year follow-up data from this study demonstrate the continued benefits of 
amifostine treatment on the incidence of grade 2 xerostomia (p = .002 versus patients who 
did not receive amifostine) (Wasserman et al., 2005). Furthermore, no significant 
differences in locoregional tumor control rate, progression-free survival time, or overall 
survival rates were observed 2 years post-treatment between the amifostine group and the 
control group (Wasserman et al., 2005).  
In another study, 50 patients with head and neck cancer were randomized to receive 
radiotherapy plus carboplatin with or without amifostine (Antonadou et al., 2002). 
Treatment interruptions were more frequent in the control group. Consequently, patients 
receiving amifostine experienced significantly shorter treatment durations (p = .013). 
Patients treated with amifostine experienced less severe acute mucositis and dysphagia; all 
patients who did not receive amifostine in the control group experienced grade 2 mucositis 
by week 3. In contrast, only 9% of patients treated with amifostine experienced grade 2 
mucositis (p < .001). By the fifth week, grade 4 mucositis was experienced by 52% and 4.5% 
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of the patients in the respective groups (p < .001). Dysphagia was similarly reduced among 
patients given amifostine. After 3 months of follow-up, grade 2 xerostomia was reported in 
27% and 74% of patients treated with and without amifostine, respectively (p < .001).  
Another consideration in the treatment of head and neck cancer is the tolerance dose of the 
parotid glands and the potential for raising this threshold with amifostine. Eisbruch et al. 
[31] reported a threshold of 26 Gy, using conformal or intensity-modulated radiotherapy, as 
a mean dose to spare parotid gland function (Eisbruch et al., 1999). With the use of 
amifostine, the threshold radiation dose for chronic xerostomia may be increased, allowing 
for greater dose coverage (Munter et al., 2007).  
1.2 Esophagitis and pneumonitis 
Damage from radiation treatment is also a major complication in the treatment of thoracic 
cancers, with higher rates of acute and late toxicity associated with concurrent 
chemoradiotherapy. Several studies have investigated the cytoprotective efficacy of 
amifostine against radiation-induced esophagitis and pneumonitis. Antonadou et al., in a 
multicenter trial of patients with advanced lung cancer, investigated whether daily 
pretreatment with amifostine could reduce the incidence of acute and late lung toxicity and 
esophagitis without affecting antitumor efficacy of radiation treatment (Antonadou et al., 
2001). One hundred forty-six patients received radiotherapy in daily fractions of 2 Gy, 5 
days per week, to a total of 55–60 Gy with or without daily amifostine, 340 mg/m2 15 
minutes before irradiation. There was a significantly lower incidence of grade 2 or higher 
pneumonitis among patients receiving amifostine (9% versus 43%; p < .001). At 6 months 
post-treatment, fibrosis was present in 53% of patients not receiving amifostine compared 
with 28% of patients receiving amifostine (p < .05). The incidence of grade 2 or higher 
esophagitis during the fourth week of treatment was 4% among patients receiving 
amifostine, compared with 42% of patients receiving radiotherapy alone (p < .001). No 
evidence of tumor protection by amifostine was noted: complete or partial responses were 
observed in 75% and 76% of patients receiving amifostine or radiotherapy alone, 
respectively.  
Komaki et al. evaluated the cytoprotective role of amifostine for esophagitis and 
hematologic and pulmonary toxicities in a randomized study of patients with stage II or III 
non-small cell lung cancer receiving concurrent chemoradiotherapy. Patients in the study 
group received amifostine, 500 mg i.v., twice weekly before chemoradiation, and patients in 
the control group received chemoradiation without Amifostine (Komaki et al., 2004). The 
median survival time was longer, but not significantly so, for patients receiving amifostine 
(26 months versus 15 months). Significantly fewer patients who received amifostine also 
received morphine to relieve severe esophagitis (7.4%) than patients who received 
chemoradiotherapy alone (31%; p = .03). Amifostine treatment was also associated with a 
significantly lower incidence of acute pneumonitis (3.7% versus 23%; p = .037). Although 
not statistically significant, 26% of patients receiving amifostine had a complete response, 
compared with 8% of patients who did not receive amifostine (p = .07).  
Despite a limited number of studies, a recent meta-analysis reported that amifostine 
treatment was observed to reduce the incidence of pneumonitis and esophagitis for patients 
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undergoing radiotherapy for lung cancer [6]. However, results from the largest multicenter 
study conducted to date were unable to show a reduction in the incidence of esophagitis with 
amifostine treatment (Movsas et al., 2005). A phase III study conducted by the RTOG (trial 
9801) treated 243 patients with favorable-prognosis inoperable stage II–IIIA/B non-small cell 
lung cancer with concurrent hyperfractionated radiotherapy plus paclitaxel (50 mg/m2) and 
carboplatin (dosed to achieve area under the concentration–time curve of 2) (Movsas et al., 
2005). Half of the patients also received i.v. amifostine (500 mg) before the afternoon radiation 
treatment. During the course of the study, esophagitis was measured via National Cancer 
Institute Common Toxicity Criteria maximum esophagitis grade, physician dysphagia log, and 
patient daily self-assessment of swallowing ability. No significant differences in esophagitis 
were observed for patients receiving amifostine compared with those who did not receive 
amifostine, with the exception of the patient-reported lower rate of swallowing dysfunction 
observed in amifostine-treated patients (z test, p = .025). The authors attributed the lack of 
significant reduction in esophagitis with amifostine to several factors, including the timing of 
amifostine administration (Movsas et al., 2005), given that preclinical studies suggest that a 
single morning dose of amifostine provides superior radioprotection than with a single 
afternoon dose (Bachy et al., 2003; Fanzenbaker et al., 2003). The randomized trials involved in 
cytoprotection for lung irradiation are shown in table 2. 
1.3 Lower gastrointestinal mucositis 
Lower gastrointestinal mucositis frequently results from pelvic irradiation. Several clinical 
trials have demonstrated that amifostine pretreatment before radiotherapy or 
chemoradiotherapy can reduce the incidence and severity of gastrointestinal toxicities that 
commonly occur following these treatments (Table 2) (Koukourakis et al., 2000; Antonadou 
et al., 2004; Athanasiou et al., 2003; Ben-Josef et al., 2002; Dunst et al., 2000; Kouloulias et al., 
2004; Kouloulias et al., 2005; Kouvaris et al., 2003; Liu et al., 1992; Simone et al., 2005; Singh 
et al., 2006). Guidelines published by the Mucositis Study Group of the Multinational 
Association of Supportive Care in Cancer/International Society for Oral Oncology 
recommend the use of amifostine (340 mg/m2) to prevent proctitis in patients receiving 
standard-dose radiotherapy (Bensadoun et al., 2006). Furthermore, these studies 
demonstrate that various routes of administration of amifostine (i.v., s.c., and intrarectal) are 
effective at reducing radiation- and chemoradiation-induced gastrointestinal toxicities in 
patients with pelvic malignancies. One study, conducted in 53 patients with prostate or 
gynecologic cancer, directly compared intrarectal amifostine administration with s.c. 
administration and found that intrarectal administration was more effective at reducing 
radiotherapy-induced rectal toxicities, whereas s.c. administration was more effective at 
reducing radiotherapy-induced urinary toxicities (Table 3) (Kouloulias et al., 2005). These 
results suggest that optimal cytoprotection may be achieved by combining routes of 
amifostine administration during treatment.  
1.4 Dermatitis 
Protection by amifostine against radiation-induced dermatitis  was assessed in a 
retrospective analysis in which 100 patients with pelvic tumors treated with radiotherapy 
and amifostine were compared with 120 historical controls who was not administered   
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Reference Radiation dose Chemotherapy Amifostine dose Comment 
Movsas et al., 
2005  
(n = 242) 
 
69.6 Gy at 1.2 Gy 
(hyperfractionation) 
Induction PC 500 mg i.v. 
4doses/wk 
between RT 
fractions 
No difference by NCI-
CTC esophagitis, 
Swallowing diaries (p < 
0.03) and weight loss (p 
< 0.05) favour amifostine 
(median survival, 15.6 
and 15.8 mo) 
Leong et al. , 
2003 
(n = 60) 
60–66 Gy at 2.0 Gy  Induction PC 740 mg/m2 with 
each chemo (Days 
1, 22, 43, 50, 57,64, 
71, 78) 
Esophagitis Grade 2–3: 
43% in amifostine, 70% 
in control (not 
significant) (median 
survival, 12.5 and 14.5 
mo) 
Senzer et al., 
2002  
(n = 63) 
 
64.8 Gy at 1.8 Gy Concurrent PC, 
gemcitabine and 
cisplatin X 3 after 
chemoradiation 
500 mg i.v. before 
weekly chemo; 200 
mg i.v. daily 
before RT 
No difference in toxicity, 
no survival data 
(ongoing trial) 
Antonadou et 
al., 2001  
(n = 146) 
55–60 Gy at 2.0 Gy.  None  340 mg/m2/d 
before RT 
↓Pneumonitis 
↓Esophagitis (no 
survival data) 
Antonadou et 
al., 2003  
(n = 73) 
55–60 Gy at 2.0Gy. Concurrent 
weekly Por C 
300 mg/m2/d 
before 
chemoradiation 
and RT 
↓esophagitis (p <0.001) 
↓pneumonitis (p = 0.009) 
(no survival data) 
Komaki et al., 
2004  
(n = 62) 
69.6 Gy at 1.2 Gy 
(hyperfractionation) 
Concurrent i.v. 
cisplatin Days 1, 
8,29, 36; Oral 
etoposide Days1–5 
8–12, 29–33,36–40 
500 mg i.v. 1st, 2nd 
day each wk 
before chemo and 
1st RT fraction  
↓Degree of esophagitis, 
↓Pneumonitis, 
↓Neutropenic fever 
(median survival,19 and 
20 mo) 
 
 
Abbreviations: P = paclitaxel; C = carboplatin; RT = radiotherapy; NCI-CTC = National Cancer Institute-
Common Toxicity Criteria. 
Table 2. Randomized trials with amifostine in lung cancer 
amifostine (Kouvaris et al., 2002). There was a 77% lower risk for radiation-induced 
dermatitis with amifostine use. The severity of dermatitis was also significantly lower 
among patients receiving amifostine compared with historical controls: the mean gross 
dermatitis scores were 0.18 ± 0.09 versus 1.0 ± 0.11 (p < .001). In another study of 40 patients 
receiving radiation treatment for pelvic tumors, grade 2 or 3 dermatitis of the 
perineal/vulvar area was observed in all patients with gynecologic and rectal cancer who 
did not receive amifostine (500 mg s.c.) (Koukourakis et al., 20000). Among patients who 
received amifostine, only grade 1 dermatitis was noted.  
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Author N  Rectal Toxicity (Control vs 
Amifostine) 
P 
Value 
Remarks 
Liu et al., 1992 100 14% vs 0% ; moderate or 
severe late toxicities 
0.03 Randomized (intravenous) 
Dunst et al., 
2000 
30 1.07±1.03 vs 0.40±0.63; 
maximum diarrhea score 
0.044 Nonrandomized 
(intravenous) 
Antonadou et 
al., 2004 
124 5.6% for amifostine vs 22.2% 
for control  
<0.011 Randomized 
Kligerman et al., 
1992 
100 5% vs 0% moderate or severe 
late toxicity 
<0.01 Randomized (intravenous) 
Kouvaris et al., 
2002 
220 Grade I/II toxicity, 70% vs 
42%  
<0.001 Nonrandomized 
(retrospective, intravenous) 
Ben-Josef et al., 
2002 
29 Grade I/II toxicity, 50% 
(500–1000 mg amifostine) vs 
15% (1500–2500 mg 
amifostine)  
0.0325 Nonrandomized 
(intrarectal) 
Koukourakis et 
al., 2000 
40 Grade III/IV observed in 
15% for control vs 0% for 
amifosine group 
<0.05 Randomized 
Kouvaris et al., 
2003 
36 Grade I/II toxicity, 88% vs 
11% 
<0.001 Randomized (intravenous) 
Muller et al., 
2004 
6 Leukocytes and lymphocytes 
irradiated were 
radioprotected  (comet assay 
measurements)  
<0.05 Nonrandomized 
Athanasiou et 
al., 2003 
205 Grade II/III acute toxicity, 
22.1% vs 5.5% (3rd wk of 
radiation) 
0.001 Randomized (intravenous) 
Kouloulias et 
al., 2004 
67 Grade I/II acute toxicity, 
44% vs 15%  for IR 
0.026 Randomized (intrarectal) 
Singh et al., 
2006; Simone et 
al., 2005 
30 33% in 1gr IR vs 0% in 2gr IR 0.06 Randomized 
Kouloulias et 
al., 2005 
53 Grade I/II acute toxicity, 
42% for s.c. Vs 11% for IR  
0.04 Randomized (subcutaneous 
vs intrarectal) 
IR=intrarectal; s.c.=subcutneous 
Table 3. Clinical Trials of Amifostine With Radiotherapy in Pelvic Tumors 
2. Different ways of administration 
2.1 i.v. Amifostine 
The American Society of Clinical Oncology guidelines for cytoprotective agents recommend 
amifostine at a dose of 200 mg/m2 daily, given as a slow i.v. push over 3 minutes, 15–30 
minutes before each fraction of radiation therapy (Hensley et al., 1999). Adverse events are 
reduced at this lower dose. Nonetheless, administration of amifostine requires close patient 
monitoring. Many patients require antiemetics. Hypotension associated with amifostine at 
this dose is less frequent but still requires close monitoring. Blood pressure should be 
measured before and immediately after the 3-minute amifostine infusion.  
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2.2 s.c. Amifostine 
The s.c. administration of amifostine has been proposed to reduce treatment-related and 
dose-limiting adverse events (Koukourakis et al., 20000). In a pharmacokinetic study, the 
plasma concentration of WR-1605 after s.c. injection of 500 mg of amifostine was 67% of that 
after a 200 mg/m2 i.v. dose (Shaw et al., 1997). Lower plasma levels of amifostine after s.c. 
injection do not necessarily translate to lower tissue concentrations. Because the amount of 
amifostine that is absorbed and converted to the active metabolites is not dependent on 
plasma pharmacokinetics, i.v. or s.c. administration may not have a significant impact on 
whether therapeutic levels are achieved in the tissues. Precise determination of the 
protective efficacy of different routes of administration will require more comprehensive 
studies that measure intracellular levels of the metabolites or assess radiation-induced DNA 
double-strand breaks in tissues after i.v. or s.c. administration of amifostine. Nonetheless, the 
efficacy of s.c. amifostine administration is best addressed in the context of a clinical trial.  
A phase II randomized trial with 140 patients assessed the feasibility, tolerance, and activity 
of the s.c. route (Koukourakis et al., 20000). A dose of amifostine of 500 mg s.c. was 
administered 20 minutes before each fraction of radiotherapy. The s.c. administration of 
amifostine was well tolerated by 85% of patients. In approximately 15% of patients, 
amifostine therapy was interrupted because of cumulative asthenia or a fever/rash reaction. 
Mild nausea was frequent (29%), and the incidence of hypotension was negligible (3%). 
Significantly less pharyngeal, esophageal, and rectal mucositis was observed among patients 
receiving amifostine (p < .04). Treatment delays because of grade 3 mucositis were 
significantly longer in patients treated with radiotherapy alone (p < .04).  
2.3 Endorectal 
Initial attempts with rectal administration of amifostine admixed in a foam did not 
demonstrate protection in patients receiving large pelvic fields of radiation (Montana et al., 
1992). However, after successful topical application of amifostine in the rectum of male rats 
(Ben-Josef et al., 1995), subsequent significant clinical benefit of endorectal administration of 
amifostine was demonstrated in a phase I study (Ben-Josef et al., 2002).  
A randomized trial of 67 patients undergoing radiotherapy for prostate cancer further 
assessed intrarectal administration of amifostine (Kouloulias et al., 2002). Patients were 
treated with or without amifostine at a dose of 1,500 mg intrarectally 20–30 minutes before 
each radiotherapy session. All patients receiving amifostine completed therapy without 
amifostine-related toxicities, suggesting that intrarectal amifostine was feasible and well 
tolerated. According to RTOG grading criteria, amifostine was superior to no treatment, 
with a significantly lower incidence of rectal mucositis (15% versus 44%; p < .04). The mean 
rectal mucositis index of patients who received amifostine was 0.3 ± 0.1 compared with 2.2 ± 
0.4 in patients without cytoprotection (p < .001). The severity of rectal mucositis was 
significantly lower in patients who received amifostine (p < .001). Urinary toxicity was 
comparable between the two groups (p = .76). A more recent study suggests that the efficacy 
of intrarectal amifostine may be dose dependent. Although not statistically significant, the 
incidence of acute grade 2 rectal mucositis was lower in patients receiving a 2-g suspension 
of amifostine (n = 12) than in those receiving 1 g (n = 18; p = .06) (Sigh et al., 2006). No breaks 
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in treatment for radiation-induced toxicities were required in that study. A combination of 
intrarectal and s.c. amifostine administration might be optimal for cytoprotection with pelvic 
irradiation. 
3. New grading scale for acute pelvic radiation induced toxicity 
The past years all the trials with amifostine and pelvic radiotherapy used as endpoints the 
WHO and RTOG/EORTC scales as shown in table 4.  
 
 Grade 
0 
Grade 1 Grade 2 Grade 3 Grade 4 
WHO 
Toxicity 
Grade  
None Increase of 2–3 
stools per d 
over 
pretreatment 
Increase of 4– 6 
stools per d, or 
nocturnal stools, or 
moderate cramping
Increase of 7–9 
stools per d, or 
incontinence, 
or severe 
cramping 
Increase of >10 stools 
per d or grossly 
bloody diarrhea, or 
need for parenteral 
support 
EORTC-
RTOG scale 
for lower 
gastro-
intestinal 
None Increased 
frequency or 
change in 
quality of 
bowel habits 
not requiring 
medication, 
rectal 
discomfort not 
requiring 
analgesics 
Diarrhea requiring 
parasympatholytic 
drugs, mucous 
discharge not 
necessitating 
sanitary pads, rectal 
or abdominal pain 
requiring analgesics
Diarrhea 
requiring 
parenteral 
support, severe 
mucous or 
blood 
discharge 
necessitating 
sanitary 
pads/abdomin
al distension 
(flat plate 
radiograph 
demonstrates 
distended 
bowel loops) 
Acute or subacute 
obstruction, fistula or 
perforation; 
gastrointestinal 
bleeding requiring 
transfusion; 
abdominal pain or 
tenesmus requiring 
tube decompression 
or bowel diversion 
 
EORTC-RTOG= European Organization for Research and Treatment of Cancer/Radiation Therapy 
Oncology Group; WHO=World Health Organization. 
Table 4. WHO Toxicity Criteria and RTOG Acute Radiation Morbidity Scoring Criteria  
A specific analytical for subjective and objective measurements was introduced. Endoscopy 
offers accurate endpoints for the evaluation of tissue damage, whereas the criteria of 
rectosigmoidoscopy findings are still not well defined in the literature. The literature deals 
mainly with symptomatic patients presenting with rectal bleeding, pain, increased stool 
frequency, urgency and incontinence, whereas systematic endoscopic analysis including 
asymptomatic patients rarely exists. A valid scoring system is essential for adequate 
description of acute rectal toxicity. For the benefit of sharing and comparing data collected 
from endoscopy after RT, we have introduced a graduation system based on 
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rectosigmoidoscopic criteria focused on acute effects and standardized terminology 
published by the European Society for Gastrointestinal Endoscopy. The scale is shown in 
table 5.  
 
 Grade 1 Grade 2 Grade 3 Grade 4 
Subjective     
Tenesmus Occasional urgency Intermittent 
urgency 
Persistent 
urgency 
Refractory 
Mucosal loss Occasional Intermittent Persistent Refractory 
Sphincter 
control 
Occasional Intermittent Persistent Refractory 
Stool frequency 2–4 per d 4–8 per d >8 per d Uncontrolled 
diarrhoea 
Pain Occasional & 
minimal 
Intermittent & 
tolerable 
Persistent & 
intense 
Refractory & 
excruciating 
Objective     
Bleeding Occult Occasionally >2 
per wk 
Persistent, daily Gross 
hemorrhage 
Mucosa surface Localized spotted, 
congested mucosa 
Punctate, 
congested 
mucosa 
Diffused, 
congested 
mucosa 
Bleeding mucosa 
Ulceration Superficial ≤1 cm2 Superficial >1 
cm2 
Deep ulcer Surgical 
intervention 
*Modification to Subjective Objective Management Analytic scale to fit radiation-induced acute toxicity 
to the rectum. Subjective and objective items were used for evaluation of acute radiation-induced rectal 
mucositis. The second and third items of the objective scale were based on findings from flexible 
rectosigmoidoscopy and were in accordance with the endoscopic terminology of the World 
Organization for Digestive Endoscopy. The final score was the sum of scores of the 8 items (score=0 in 
the absence of toxicity). 
Table 5. Rectal Toxicity Grade*  
Our experience has shown that the terminology is practicable and provides a definition of 
terms usable by radiation oncologist and endoscopists. The S-RS scale showed a satisfied 
clinical validity and reliability (Kouvaris etal., 2003). In a previous publication (Kouloulias et 
al., 2004) the rectosigmoidoscopic findings for amifostine versus no amifostine showed 
significant differences, as shown in figure 1.  
4. Conclusion 
Normal tissues vary in the extent that they are protected from radiation damage by 
amifostine. Because amifostine does not cross the blood–brain barrier, the central nervous 
system, often the dose-limiting organ in radiotherapy, is not protected (Millar et al., 1982; 
Washburn et al., 1976). Protection factors for other tissues range from three in the 
hematopoietic system and salivary glands to approximately one in the lung, kidney, and 
bladder (Rojas et al., 1984; Rojas et al., 1986; Travis 1984). Within the same tissues, a range of 
protection factors has been reported (Rojas et al., 1984; Mori et al., 1984). Discrepancies in 
WR-1065 concentrations in tissues within 15–30 minutes of administration (Utley et al., 1984) 
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and the normal interval between administration of amifostine and radiotherapy may explain 
these differences. Nonhomogenous distribution of amifostine and its metabolites within a 
tissue, even at the level of the DNA (savoye et al., 1997), may also contribute to this 
heterogeneity.  
 
Fig. 1. Rectosigmoidoscopic findings. Panels A and B illustrate a regular rectal mucosa in 
patients after intrarectal administration of amifostine. Panels C and D are from patients who 
did not receive amifostine and illustrate congested mucosa with superficial ulceration >1 
cm2 (indicated by the arrows).  
The U.S. Food and Drug Administration has approved the i.v. use of amifostine to reduce 
the cumulative renal toxicity associated with repeated administration of cisplatin in patients 
with advanced ovarian cancer and to reduce the incidence of moderate to severe xerostomia 
in patients undergoing postoperative radiation treatment for head and neck cancer, where 
the radiation port includes a substantial portion of the parotid glands. Amifostine has been 
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proven to be a useful addition to the arsenal of the radiation oncologist, helping improve 
patients' quality of life and in some cases allowing more aggressive radio- and 
chemotherapeutic regimens. Currently, s.c. administration of amifostine is a standard 
practice for patients with head and neck cancer as well as for patients with recurrent ovarian 
carcinoma (Hensley et al., 2009), while there is evidence now that the s.c is not superior to 
i.v. administration of amifostine (Bardet et al., 2011). Refinements in doses and 
administration of amifostine lead to constant improvement in the adverse event profile, 
resulting in fewer interruptions in treatment and ultimately improving patient outcomes 
(Jellena et al., 2006; Bourhis et al., 2011). At last but not least, recent meta-analysis from 16 
randomized trials (1,554 patients) confirmed the lack of any tumor protection in routine 
radiotherapy practice when amifostine is administered (Bourhis et al., 2011). 
It has to be mentioned that the graduation system designed by our group is user-friendly 
and more than this, it is an interface between radiation-oncologists and gastroenterologists 
by means of common terminology between specializations for radiation induced rectal 
toxicity.   
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Cancer is the leading cause of death in economically developed countries and the second leading cause of
death in developing countries. It is an enormous global health encumbrance, growing at an alarming pace.
Global statistics show that in 2030 alone, about 21.4 million new cancer cases and 13.2 million cancer deaths
are expected to occur, simply due to the growth, aging of the population, adoption of new lifestyles and
behaviors. Amongst the several modes of treatment for cancer available, Radiation treatment has a major
impact due to technological advancement in recent times. This book discusses the pros and cons of this
treatment modality. This book "Modern Practices in Radiation Therapy" has collaged topics contributed by top
notch professionals and researchers all around the world.
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